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  41 
BACKGROUND 42 
In a phase 2 trial, lenvatinib, an inhibitor of vascular endothelial growth factor receptor 1‒3, fibroblast 43 
growth factor receptor 1‒4, platelet-derived growth factor receptor alpha, RET, and KIT, showed activity 44 
in hepatocellular carcinoma (HCC). We aimed to compare overall survival in patients treated with 45 
lenvatinib versus sorafenib as first-line treatment for unresectable HCC.  46 
METHODS 47 
This open-label, phase 3, multicentre, noninferiority trial involving patients with unresectable HCC who 48 
had not received treatment for advanced disease randomised 478 to lenvatinib (body weight ≥60 kg: 12 49 
mg/day; <60 kg: 8 mg/day) and 476 to twice-daily sorafenib 400 mg. The primary endpoint was overall 50 
survival. The noninferiority margin was set at 1·08. Registered with ClinicalTrials.gov, number: 51 
NCT01761266. 52 
FINDINGS 53 
Patients were enrolled from March 1, 2013 through July 30, 2015. The study met its primary endpoint of 54 
noninferiority in overall survival for lenvatinib versus sorafenib (medians: lenvatinib, 13·6 months vs. 55 
sorafenib, 12·3 months; hazard ratio [HR]: 0·92; 95% confidence interval [CI], 0·79 to 1·06). The most 56 
common any-grade adverse events were hypertension (201 [42·2%]), diarrhoea (184 [38·7%]), 57 
decreased appetite (162 [34·0%]), and decreased weight (147 [30·9%]) for lenvatinib, and palmar-58 
plantar erythrodysaesthesia (249 [52·4%]), diarrhoea (220 [46·3%]), hypertension (144 [30·3%]), and 59 
decreased appetite (127 [26·7%]) for sorafenib. In the EORTC-QLQ-based analysis, there were 5 60 
outcomes, including pain and diarrhoea with nominal p<0.05, all of which favoured lenvatinib compared 61 
to sorafenib. 62 
INTERPRETATION 63 
Lenvatinib was noninferior to sorafenib in overall survival in untreated advanced HCC. The safety and 64 
tolerability profiles of lenvatinib were consistent with those previously observed. 65 
FUNDING: Eisai  66 
 67 
 68 
Research in Context 69 
Evidence before this study 70 
A PubMed literature search (March 16, 2017) for “phase 3” [Title/Abstract] OR “phase III” 71 
[Title/Abstract] AND “hepatocellular carcinoma” [MeSH Terms], restricted to clinical trials, yielded 65 72 
reports. Of these, 21 publications described the use of targeted agents for the treatment of 73 
hepatocellular carcinoma, 11 of which were studies of single-agent sorafenib and 3 of which were 74 
studies of sorafenib in combination with another agent. There were 5 trials investigating targeted agents 75 
following treatment with sorafenib and 4 trials in first-line treatment of hepatocellular carcinoma with 76 
sorafenib as the comparator. None of these 4 trials met their primary endpoints of noninferiority or 77 
superiority over sorafenib in overall survival.  78 
Added value of this study 79 
This is the first global phase 3 trial to meet its primary endpoint of noninferiority in overall survival 80 
against sorafenib as first-line treatment for hepatocellular carcinoma in 10 years. Furthermore, 81 
lenvatinib demonstrated statistically significant and clinically meaningful improvement in all secondary 82 
endpoints (progression-free survival, time to progression, and objective response rate) with a 83 
reasonable safety profile.  84 
Implications of all the available evidence 85 
The results of this study support lenvatinib as a first-line treatment option for patients with unresectable 86 
hepatocellular carcinoma. 87 
 88 
  89 
INTRODUCTION 90 
Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide and is responsible 91 
for nearly 745,000 deaths each year.1 It usually occurs in a background of chronic liver disease, 92 
particularly in cirrhosis, which limits the feasibility of surgical resection.2,3 Sorafenib, an oral multikinase 93 
inhibitor, is the only systemic therapy that has been proven to extend overall survival when used as a 94 
first-line treatment for HCC, demonstrating a median improvement of 2.8 months compared with 95 
placebo (10·7 months vs 7·9 months; hazard ratio [HR] 0·69; p<0·001) despite a low response rate of 96 
2%.4 In patients from the Asia-Pacific region who were taking sorafenib, the median improvement in 97 
overall survival over placebo was 2·3 months (6·5 months vs 4·2 months; HR 0·68; p=0·014).5 98 
Drug development in HCC in the past 10 years is marked by 4 failed global phase 3 trials (of sunitinib, 99 
brivanib, linifanib, and erlotinib plus sorafenib) that did not demonstrate noninferiority6-8 or superiority9 100 
to sorafenib in overall survival in first-line treatment of HCC. There are currently no approved first-line 101 
systemic treatments available for advanced unresectable HCC other than sorafenib. Only regorafenib is 102 
approved as second-line systemic treatment for patients who failed to respond to sorafenib.10 Best 103 
supportive care or participation in clinical trials is currently recommended by the treatment guidelines in 104 
the second-line setting.11 Therefore, due to the current paucity of systemic treatment options for 105 
patients with advanced HCC, a critical need exists to develop new agents for the effective management 106 
of this disease.   107 
Lenvatinib is an oral multikinase inhibitor that targets vascular endothelial growth factor (VEGF) 108 
receptors 1, 2, and 3; fibroblast growth factor (FGF) receptors 1, 2, 3, and 4; platelet-derived growth 109 
factor receptor α (PDFGRα), RET, and KIT.12-15 Lenvatinib monotherapy was approved for the treatment 110 
of radioiodine-refractory differentiated thyroid cancer.16 Lenvatinib and everolimus were approved as a 111 
combined treatment for advanced renal cell carcinoma following 1 prior anti-angiogenic therapy.17 In a 112 
phase 2 study of patients with advanced HCC, lenvatinib at a dose of 12 mg once daily showed clinical 113 
activity and had an acceptable safety profile.18 Based on dose adjustments depending on body weights 114 
as well as pharmacokinetic modelling data,19 a starting dose of lenvatinib based on body weight was 115 
adopted (12 mg and 8 mg once daily for patients with body weights ≥60 kg and <60 kg, respectively) for 116 
further clinical development in HCC. Given the efficacy signal observed in this phase 2 study, we 117 
performed a phase 3 randomised, open-label, noninferiority study to compare the efficacy and safety of 118 
lenvatinib versus sorafenib as first-line treatment for unresectable HCC. 119 
 120 
METHODS 121 
Study Design 122 
This multicentre, phase 3, randomised, open-label, noninferiority study was conducted at 154 sites in 20 123 
countries throughout the Asia-Pacific, European, and North American regions. Within stratification 124 
factors, patients were randomly assigned (1:1) to receive oral lenvatinib at a dose of 12 mg per day (for 125 
body weight ≥60 kg) or 8 mg per day (for body weights <60 kg) or sorafenib at doses of 400 mg twice 126 
daily in 28-day cycles. Dosage interruptions followed by reductions for lenvatinib-related toxicities (to 8 127 
and 4 mg per day, or 4 mg every other day) were permitted. Modifications to sorafenib dosage were 128 
implemented according to prescribing information in each region (all patients in the sorafenib arm 129 
received a starting dose of 400 mg orally twice per day). 130 
 131 
Study Eligibility 132 
Patients who were eligible for enrolment had unresectable HCC with diagnosis confirmed histologically 133 
or cytologically or with diagnosis confirmed clinically in accordance with the American Association for 134 
the Study of Liver Diseases criteria. Included patients also had 1 or more measurable target lesion 135 
(lesions previously treated with radiotherapy or locoregional therapy had to show radiographic evidence 136 
of disease progression to be deemed a target lesion), based on modified Response Evaluation Criteria in 137 
Solid Tumours (mRECIST)20; Barcelona Clinic Liver Cancer stage B or C categorisation21; Child-Pugh class 138 
A; and Eastern Cooperative Oncology Group performance status score of 0 or 1. All eligible patients had 139 
controlled blood pressure (≤150/90 mm Hg), adequate liver function (defined as: albumin ≥ 2·8 g/dL, 140 
bilirubin ≤ 3·0 mg/dL, and aspartate aminotransferase, alkaline phosphatase, and alanine 141 
aminotransferase ≤ 5 times the upper limit of normal), and adequate blood (hemoglobin ≥ 8·5 g/dL, 142 
platelet count ≥ 75 × 109/L, and international normalized ratio ≤2·3), renal, and pancreatic function. 143 
Patients with ≥50% liver occupation, obvious invasion of the bile duct, or portal vein invasion at the 144 
main portal vein were excluded. Patients also were excluded if they had received prior systemic therapy 145 
for HCC. 146 
Study Oversight 147 
The study was approved by all relevant institutional review boards and was conducted in accordance 148 
with the Declaration of Helsinki and local laws. The trial was registered before the start of patient 149 
enrolment. All patients provided written informed consent before undergoing any study-specific 150 
procedures. The study was funded by Eisai (Woodcliff Lake, NJ) and designed in collaboration with the 151 
principal investigators. The study was overseen by an independent data monitoring committee. All 152 
parties vouch for the accuracy and completeness of the data and analyses and for adherence to the 153 
study protocol. The manuscript was prepared by the authors with assistance from professional medical 154 
writers who were funded by Eisai. Revisions were contributed by the authors. 155 
Randomisation and Masking 156 
Patients were randomly allocated in a 1:1 ratio to receive either lenvatinib or sorafenib. The funder 157 
provided lenvatinib. Because the study was open label, the treatments allocated were not masked to 158 
the patients or investigators. Allocation was performed with an interactive voice/web-response system 159 
with region (Asia-Pacific or Western) macroscopic portal vein invasion or extrahepatic spread or both 160 
(yes or no), Eastern Cooperative Oncology Group performance status (0 or 1), and body weight (<60 kg 161 
or ≥60 kg) as stratification factors. 162 
Endpoints and Assessments 163 
The primary endpoint was overall survival. Secondary endpoints included progression-free survival, time 164 
to progression, objective response rate, quality-of-life measurements including the European 165 
Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-166 
C30)22,23 and the HCC-specific EORTC QLQ-HCC1824 health questionnaires, and plasma pharmacokinetic 167 
exposure parameters. All efficacy evaluations were based on the full analysis set (all randomised 168 
patients). 169 
The investigators evaluated tumours in each treatment arm in accordance with mRECIST.20,25 The liver 170 
was examined with computed tomography or magnetic resonance imaging using a triphasic scanning 171 
technique. Assessments were performed every 8 weeks (irrespective of dosage interruptions) until 172 
radiologic disease progression. Patients who discontinued from study treatment without disease 173 
progression continued to have tumour assessments performed every 8 weeks or until disease 174 
progression or the start of another anticancer treatment. Quality-of-life questionnaires were 175 
administered at baseline, on day 1 of each subsequent treatment cycle, and at the off-treatment visit. 176 
Safety assessments included recording of vital signs, haematologic, and biochemical laboratory testing, 177 
urinalysis, and electrocardiography. Adverse events were graded according to the National Cancer 178 
Institute Common Terminology Criteria for Adverse Events version 4·0.26 All safety evaluations were 179 
based on the safety analysis set (all patients who received at least 1 dose of study treatment). Post hoc 180 
exploratory tumour assessments using mRECIST and RECIST v1·1 were performed by blinded central 181 
independent imaging review (IIR). 182 
A population pharmacokinetic analysis for lenvatinib was conducted to derive individual 183 
pharmacokinetic parameters and lenvatinib exposures for this study. The dataset used in the analysis 184 
included lenvatinib plasma concentrations from 468 patients with HCC in this study and lenvatinib 185 
plasma concentrations pooled from 12 additional studies (phase 1 to 3) in healthy individuals and in 186 
patients with other tumor types (e.g. differentiated thyroid cancer).  187 
 188 
Statistical Analysis 189 
The primary endpoint of overall survival was first tested for noninferiority, then for superiority. The 190 
required number of events for the primary analysis was 700 deaths.  191 
The HR and its 95% confidence interval (CI) were estimated from a Cox proportional hazard model  192 
with treatment group as a factor and with the analysis stratified according to the same factors applied 193 
for randomisation for the primary and for the subgroup analyses where it is appropriate. For the 194 
subgroup analysis, the analyses were performed within each subgroup. The noninferiority margin was 195 
set at 1·08 based on previous phase 3 trials of sorafenib.4,5 Noninferiority was declared if the upper limit 196 
of the 2-sided 95% CI for HR was <1·08. 197 
A fixed-sequence procedure was followed to control the overall type I error rate of analyses for both the 198 
primary and secondary efficacy endpoints at α=0·05 (2-sided). After noninferiority was declared, 199 
secondary efficacy endpoints were tested. Differences in progression-free survival and time to 200 
progression were evaluated using a stratified log-rank test with randomisation stratification factors, with 201 
the associated HR and its 95% CI. The same method was used to evaluate differences in progression-free 202 
survival and time to progression in the subgroup analyses. A difference in the objective response rate 203 
was evaluated using the Cochran-Mantel-Haenszel chi-square test with randomisation stratification 204 
factors as strata, with associated odds ratio and its 95% CI. To assess futility, two interim analyses (at 205 
30% and 70% of the target number of events) were performed using Bayesian predictive probability in a 206 
noninferiority design by the independent data monitoring committee. Programming and statistical 207 
analyses were performed with SAS version 9 or higher.  208 
Role of the funding source: 209 
The funder employed CD, MG, KS, SK, TT, and MR, who played a significant role in study design, data 210 
collection, data analysis, data interpretation, and writing of the report (see Contributors for details). The 211 
corresponding author had full access to all data in the study and had final responsibility for the decision 212 
to submit for publication. 213 
RESULTS 214 
Patients 215 
Patients were recruited from March 1, 2013 through July 30, 2015. A total of 954 patients from 20 216 
countries were randomly assigned to receive lenvatinib (478 patients) or sorafenib (476 patients) (Figure 217 
S1 in the Supplementary Appendix). The required number of 700 deaths occurred after the completion 218 
of enrolment. The efficacy analysis followed the intent-to-treat principle. Only patients who received 219 
treatment (lenvatinib, n=476 patients; sorafenib, n=475 patients) were included in the safety analysis. 220 
Patient characteristics at baseline were well balanced between treatment groups, with the exception of 221 
baseline hepatitis C aetiology and alpha-fetoprotein levels (Table 1). At the time of data cutoff 222 
(November 13, 2016), the median duration of follow-up was 27·7 months (interquartile range [IQR], 23·3 223 
to 32·8) in the lenvatinib group and 27·2 months (IQR, 22·6 to 31·2) in the sorafenib group. 224 
Efficacy 225 
Lenvatinib demonstrated noninferiority in overall survival compared with sorafenib. The median overall 226 
survival was 13·6 months (95% CI, 12·1 to 14·9) with lenvatinib, compared with 12·3 months (95% CI, 227 
10·4 to 13·9) with sorafenib (HR: 0·92; 95% CI, 0·79 to 1·06) (Figure 1A; results from the per protocol set 228 
are shown in Table S1 in the Supplementary Appendix). The effect of lenvatinib and sorafenib on median 229 
overall survival was consistent across the subgroups based on baseline characteristics (Figure 2A). While 230 
baseline alpha-fetoprotein level was not a pre-specified stratum, patients with baseline alpha-231 
fetoprotein levels <200 ng/mL had longer overall survival than those with alpha-fetoprotein levels ≥200 232 
ng/mL in both treatment groups (Figure 2A). There were more patients with baseline alpha-fetoprotein 233 
levels <200 ng/mL in the sorafenib arm (286, 60·1%) compared with the lenvatinib arm (255, 53·3%, 234 
Table 1).   235 
Lenvatinib demonstrated a statistically significant improvement compared to sorafenib in all secondary 236 
efficacy endpoints as determined by investigators’ tumour assessment based on mRECIST. Median 237 
progression-free survival for lenvatinib was 7·4 months (95% CI, 6·9 to 8·8 months) compared with 3·7 238 
months (95% CI, 3·6 to 4·6 months) with sorafenib (HR: 0·66; 95% CI, 0·57 to 0·77; p<0·0001) (Figure 1B). 239 
The median time to progression was 8·9 months (95% CI, 7·4 to 9·2 months) for patients in the 240 
lenvatinib group compared with 3·7 months (95% CI, 3·6 to 5·4 months) for patients in the sorafenib 241 
group (HR: 0·63; 95% CI, 0·53 to 0·73; p<0·0001) (Table 2 and Figure S2 in the Supplementary Appendix). 242 
Lenvatinib showed an objective response rate of 24·1% versus 9·2% for sorafenib (odds ratio, 3·13; 95% 243 
CI, 2·15 to 4·56; p<0·0001) (Table 2 and Figure S3 in the Supplementary Appendix). The improvements in 244 
all secondary efficacy endpoints (progression-free survival, time to progression, and objective response 245 
rate) with lenvatinib over sorafenib are consistent across all predefined subgroups (Figure 2B, and 246 
Figures S4 and S5 in the Supplemental Appendix). Analysis for overall survival with predefined subgroups 247 
supports the robustness of the noninferiority result (Table S2 in the Supplementary Appendix). Blinded 248 
IIR confirmed progression-free survival (HR: 0·64; 95% CI, 0·55–0·75; p<0·0001) and time to progression 249 
(HR: 0·60; 95% CI, 0·51–0·71; p<0·0001) based on investigator assessments according to mRECIST (Table 250 
2). Similar progression-free survival and time to progression were observed for mRECIST and RECIST 1·1 251 
based on blinded IIR. Blinded IIR confirmed a significantly higher objective response rate in the 252 
lenvatinib arm compared with the sorafenib arm by mRECIST (40·6% vs. 12·4%; odds ratio: 5·01; 95% CI, 253 
3·59–7·01; p<0·0001) and RECIST 1·1 (18·8% vs. 6·5%; odds ratio: 3·34; 95% CI, 2·17–5·14; p<0·0001; 254 
Table 2). 255 
Of note, 156 (32·6%) patients in the lenvatinib arm and 184 (38·7%) in the sorafenib arm received a 256 
post-study anticancer medication (including investigational therapy). Of these, 121 (25·3%) patients in 257 
the lenvatinib arm and 56 (11·8%) in the sorafenib arm, respectively, received sorafenib during survival 258 
follow-up. In the Western region, 41 (26·1%) patients in the lenvatinib arm received any anticancer 259 
medication during survival follow-up versus 61 (38·9%) in the sorafenib arm. In the lenvatinib arm, 11 260 
(7·0%) patients in the Western region had any anticancer procedure during follow-up compared with 18 261 
(11·5%) patients in the sorafenib arm in this region (Table S3 in the Supplementary Appendix). 262 
 263 
Safety and Side-effect Profile 264 
Median duration of study treatment for patients in the lenvatinib group was longer than for patients in 265 
the sorafenib group (5·7 vs. 3·7 months). Treatment-emergent adverse events occurred in 98·7% of 266 
patients who received lenvatinib and 99·4% of patients who received sorafenib. Adjusted by patient-267 
years, the adverse event rate was 18·9 in the lenvatinib group and 19·7 in the sorafenib group. 268 
Treatment-emergent adverse events of grade 3 or higher occurred in 75·0% of patients who received 269 
lenvatinib and 66·5% of patients who received sorafenib (adverse event rate/patient-year: 3·2 vs. 3·3). 270 
The most common treatment-emergent adverse events among patients who received lenvatinib were 271 
hypertension (201; 42·2%), diarrhoea (184; 38·7%), decreased appetite (162; 34·0%), and decreased 272 
weight (147; 30·9%). In the sorafenib arm, the most common treatment-emergent adverse events were 273 
palmar-plantar erythrodysaesthesia (52·4%), diarrhoea (46·3%), hypertension (30·3%), and decreased 274 
appetite (26·7%) (Table 3).  275 
Fatal adverse events occurred throughout treatment and appeared to occur at similar rates in both 276 
arms. Fatal adverse events determined by the investigator to be related to lenvatinib treatment 277 
occurred in 11 patients (2·3%) and included hepatic failure (3 patients), cerebral haemorrhage  278 
(3 patients), and respiratory failure (2 patients). In the sorafenib group, treatment-related fatal adverse 279 
events occurred in 4 patients (0·8%) and included tumour haemorrhage, ischaemic stroke, respiratory 280 
failure, and sudden death (1 event per patient). 281 
Treatment-related treatment-emergent adverse events leading to lenvatinib drug interruption, dose 282 
reduction, and drug withdrawal occurred in 190 (39·9%), 176 (37·0%), and 42 (8·8%) patients, 283 
respectively. In the sorafenib arm, treatment-related treatment-emergent adverse events led to drug 284 
interruption, dose reduction, and drug withdrawal in 153 (32·2%), 181 (38·1%), and 34 (7·2%) patients, 285 
respectively. The mean lenvatinib dose intensity was 7·0 mg in the 8 mg/day group and 10·5 mg in the 286 
12 mg/day group, corresponding to 87·7% and 87·5% of the planned starting doses, respectively. The 287 
mean sorafenib dose intensity was 663·8 mg, or 83·0% of the planned starting dose.  288 
Quality of Life 289 
Baseline scores on the EORTC QLQ-C30 and EORTC QLQ-HCC18 health questionnaires were similar in the 290 
lenvatinib and sorafenib treatment groups. Following treatment, scores declined in both groups. The 291 
analysis of time to clinically meaningful deterioration showed that role functioning (nominal p=0.0193), 292 
pain (nominal p=0.0105), and diarrhoea (nominal p<0.0001) from QLQ-C30 and nutrition (nominal 293 
p=0.0113) and body image (nominal p=0.0051) from QLQ-HCC18 deterioration was observed earlier in 294 
patients treated with sorafenib than with lenvatinib. For between-group comparison, the summary 295 
score was not significantly different between the treatment arms (HR 0·87; 95%CI 0·754–1·012; Figure 296 
S6 in the Supplementary Appendix). 297 
Pharmacokinetics 298 
Based on the individual model-derived, predicted lenvatinib area under the curve (AUC) values at steady 299 
state for patients with HCC in the current study, the median value and range of AUC are comparable 300 
between the group with a starting dose of 8 mg for body weight < 60 kg (median: 1820.2 ng·h/mL; min-301 
max: 704.8–4980.7 ng·h/mL) and the group with a 12 mg starting dose for body weight ≥ 60 kg (median: 302 
1996.0 ng·h/mL; min-max: 925.5 - 5427.9 ng·h/mL), which supports the starting dose of 8 mg for body 303 
weight < 60 kg, and confirms the weight-based dosing based on the pharmacokinetic analysis from the 304 
Phase 1/2 study in HCC subjects.19 There were no differences in lenvatinib oral clearance or in AUC at 305 
steady state among Western, Asian, Chinese and Japanese populations in the current study.  306 
DISCUSSION 307 
This is the first positive global phase 3 trial (HR 0·92; upper bound of 95% CI 1·06) for overall survival 308 
compared with sorafenib in first-line treatment for HCC in 10 years and the first ever to be positive using 309 
an active-control arm. This study showed lenvatinib to be noninferior to sorafenib, currently the 310 
standard of care in HCC, for overall survival. Importantly, lenvatinib demonstrated statistically 311 
significant, clinically meaningful improvement for all secondary efficacy endpoints (progression-free 312 
survival, time to progression, and objective response rate) across subgroups, as well as in quality-of-life 313 
assessments. Together, these data support the overall survival result in this study. 314 
The median overall survival of patients who received sorafenib in the current study (12·3 months) is 315 
longer than has been reported in any previous large randomised phase 3 study.4–9 One possible 316 
explanation for this result is the higher proportion of post-sorafenib anticancer therapy observed in this 317 
study. For example, 21% and 17% of patients receiving sorafenib in the previous phase study of brivanib 318 
vs. sorafenib received systemic and nonsystemic post-sorafenib treatments, respectively compared with 319 
39% and 27% of patients receiving sorafenib in this study.7 Continuous improvements in care for 320 
unresectable HCC have been made, and multimodality therapies, including locoregional treatment 321 
approaches, are now often used following progression because they may be efficacious even after 322 
systemic therapies such as sorafenib treatment.27,28 If post-progression survival is prolonged by such 323 
post-study treatments, this may lead to a dilution of the observed overall survival treatment benefit. 324 
Hence, while still representing the gold standard, overall survival as an endpoint alone for trials in first 325 
line HCC may no longer capture the full extent of antitumour efficacy. The significant improvement in 326 
progression-free survival, time to progression, and objective response rate with lenvatinib in this study 327 
may indicate, as in some other tumours, the emergence of a broader paradigm in drug assessment and 328 
treatment in advanced HCC.  329 
This study did not enroll patients with >50% liver involvement and main portal vein invasion 330 
because this exclusion criterion was used in the preceding phase 2 proof-of-concept study conducted in 331 
Japan as mandated by Japan Society of Hepatology consensus-based clinical practice guidelines.17,29 This 332 
resulted in only 4.2% screen failures in the phase 3 study. While this could have only slightly changed the 333 
overall prognosis of the patient population, it did not affect distribution of patients between the study 334 
arms since this was controlled by the randomization.  335 
The safety profile of lenvatinib is consistent with that observed in previous studies.16,18,30 Patients who 336 
received lenvatinib experienced fewer instances of palmar-plantar erythrodysaesthesia, diarrhoea, and 337 
alopecia, and more instances of hypertension, proteinuria, dysphonia, and hypothyroidism than did 338 
patients who received sorafenib. Although quality-of-life scores declined in both groups after treatment, 339 
a clinically meaningful delay in deterioration for multiple domains was observed with lenvatinib 340 
compared with sorafenib. 341 
The median duration of lenvatinib treatment was 1·5 times longer than that of sorafenib, which may 342 
have contributed to the higher incidence of adverse events. When adjusted for treatment duration, 343 
almost all episodes were comparable for the lenvatinib and sorafenib arms. The dosages of lenvatinib 344 
for HCC are lower than the lenvatinib dosage for radioiodine-refractory differentiated thyroid cancer (24 345 
mg per day). In the phase 1 study of lenvatinib in HCC, patients with HCC who received 12 mg of 346 
lenvatinib per day and patients with solid tumours who received 25 mg of lenvatinib per day had similar 347 
lenvatinib plasma concentration at 24 hours, possibly because lenvatinib is metabolised in the liver.31 348 
Unlike other cancer types, including differentiated thyroid cancer and renal cell carcinoma, lenvatinib 349 
pharmacokinetics were affected by body weight to a clinically significant degree. The final 350 
pharmacokinetic model for lenvatinib included body weight effect as an allometric constant on both 351 
clearance and volume parameters, whereby both parameters increased with increasing body weight. 352 
The clinical relevance of this finding is that, when administered equivalent doses, HCC subjects with low 353 
body weights will have clinically significant higher exposures than patients with high body weights, 354 
supporting body weight-based dosing.   355 
This study was potentially limited by its open-label design. However, because of the distinct toxicities 356 
and dose management requirements, the open-label design was essential to ensure patient safety. Still, 357 
major protocol deviations were minimal and balanced, the percentage of patients experiencing clinical 358 
progression and drug discontinuations were similar in both arms, and the results were confirmed by 359 
blinded IIR. Therefore, we believe any bias introduced by the open-label design was minimal. It should 360 
also be noted that the full analysis set was used as the primary analysis set as opposed to the per-361 
protocol set. However, the sample size calculation for this study was such that any factor introducing 362 
bias toward the null hypothesis would reduce the power of the study. For this reason, use of the full 363 
analysis set as the primary analysis set for noninferiority testing is a conservative approach in this study, 364 
and, in fact, overall survival analysis based on the per-protocol set was completely consistent with that 365 
based on the full analysis set. 366 
The use of mRECIST may also be considered as a limitation of the study. However, mRECIST has been 367 
established as a tool in HCC.32,33 In addition, the exploratory post-hoc analysis confirms that progression-368 
free survival and time to progression based on investigator assessment using mRECIST are similar to 369 
those observed based on IIR using both mRECIST and RECIST 1.1. 370 
In conclusion, the results of this study demonstrated noninferiority of lenvatinib versus sorafenib in 371 
overall survival, and statistically significant and clinically meaningful improvement in progression-free 372 
survival, time to progression, and objective response rate. The safety profiles of lenvatinib and sorafenib 373 
in this study appear consistent with the known safety profiles of these agents in HCC, and no new safety 374 
signals were identified. Based on these results, lenvatinib may be a potential new treatment option in 375 
advanced HCC. 376 
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  539 
Table 1. Demographic and Disease Characteristics at Baseline. 540 
 Lenvatinib 
(n = 478) 
Sorafenib 
(n = 476) 
Total 
(N = 954) 
Age ‒ y 
Mean  
Standard Deviation 
 
61·3  
11·7 
 
61·2  
12·0 
 
61·3 
11·8 
Age group — no. (%) 
<65 y 
≥65 to <75 y 
≥75 y 
 
 270 (56·5) 
150 (31·4) 
58 (12·1) 
 
283 (59·5) 
126 (26·5) 
67 (14·1) 
 
553 (58·0) 
276 (28·9) 
125 (13·1) 
Sex — no. (%) 
Male 
Female 
 
405 (84·7) 
73 (15·3) 
 
401 (84·2) 
75 (15·8) 
 
806 (84·5) 
148 (15·5) 
Region — no. (%) 
Western 
Asia-Pacific 
 
157 (32·8) 
321 (67·2) 
 
157 (33·0) 
319 (67·0) 
 
314 (32·9) 
640 (67·1) 
Race — no. (%) 
White 
Asian 
 
135 (28·2) 
334 (69·9) 
 
141 (29·6) 
326 (68·5) 
 
276 (28·9) 
660 (69·2) 
Body weight (kg) — no. (%) 
<60  
≥60  
 
153 (32·0) 
325 (68·0) 
 
146 (30·7) 
330 (69·3) 
 
299 (31·3) 
655 (68·7) 
Eastern Cooperative Oncology Group 
performance status — no. (%) 
0 
1 
 
 
304 (63·6) 
174 (36·4) 
 
 
301 (63·2) 
175 (36·8) 
 
 
605 (63·4) 
349 (36·6) 
Child-Pugh class — no. (%) 
A 
B 
 
475 (99·4) 
3 (0·6) 
 
471 (98·9) 
5 (1·1) 
 
946 (99·2) 
8 (0·8) 
Macroscopic portal vein invasion — 
no. (%) 
Yes 
No 
 
 
109 (22·8) 
369 (77·2) 
 
 
90 (18·9) 
386 (81·1) 
 
 
199 (20·9) 
755 (79·1) 
Extrahepatic spread — no. (%) 
Yes  
No 
 
291 (60·9) 
187 (39·1) 
 
295 (62·0) 
181 (38·0) 
 
586 (61·4) 
368 (38·6) 
Macroscopic portal vein invasion, 
extrahepatic spread, or both — no. 
(%) 
Yes 
No 
 
 
 
329 (68·8) 
149 (31·2) 
 
 
 
336 (70·6) 
140 (29·4) 
 
 
 
665 (69·7) 
289 (30·3) 
Underlying cirrhosis based on blinded 
IIR — no. (%) 
Yes 
No 
 
 
356 (74·5) 
122 (25·5) 
 
 
364 (76·5) 
112 (23·5) 
 
 
720 (75·5) 
234 (24·5) 
Barcelona Clinic Liver Cancer stage — 
no. (%) 
B (intermediate stage) 
C (advanced stage) 
 
 
104 (21·8) 
374 (78·2) 
 
 
92 (19·3) 
384 (80·7) 
 
 
196 (20·5) 
758 (79·5) 
Involved disease sites — no. (%) 
Liver 
Lung 
 
441 (92·3) 
163 (34·1) 
 
430 (90·3) 
144 (30·3) 
 
871 (91·3) 
307 (32·2) 
Involved disease sites per patient — 
no. (%) 
1 
2 
≥3 
 
 
207 (43·3) 
167 (34·9) 
103 (21·5) 
 
 
207 (43·5) 
183 (38·4) 
86 (18·1) 
 
 
414 (43·4) 
350 (36·7) 
189 (19·8) 
Aetiology of chronic liver disease — 
no. (%) 
Hepatitis B 
Hepatitis C 
Alcohol 
Other 
Unknown 
 
 
251 (52·5) 
91 (19·0) 
36 (7·5) 
38 (7·9) 
62 (13·0) 
 
 
228 (47·9) 
126 (26·5) 
21 (4·4) 
32 (6·7) 
69 (14·5) 
 
 
479 (50·2) 
217 (22·7) 
57 (6·0) 
70 (7·3) 
131 (13·7) 
Baseline alpha-fetoprotein level —
ng/mL 
No. of patients 
Mean  
Standard deviation 
 
 
471 
17507·7  
105137·4 
 
 
463 
16678·5  
94789·5 
 
 
934 
17096·5 
100088·8 
Median  
Range 
133·1  
0−1567470 
71·2 
0−1446396 
89·0 
0−1567470 
Baseline alpha-fetoprotein level 
group (ng/mL) — no. (%) 
<200  
≥200 
Missing 
 
 
255 (53·3) 
222 (46·4) 
1 (0·2) 
 
 
286 (60·1) 
187 (39·3) 
3 (0·6) 
 
 
541 (56·7) 
409 (42·9) 
4 (0·4) 
Concomitant systemic antiviral 
therapy for hepatitis B or C — no. (%) 
 
163 (34·1) 
 
149 (31·3) 
 
312 (32·7) 
Prior therapy — no. (%) 
Prior anticancer procedures 
Radiotherapy 
 
327 (68·4) 
49 (10·3) 
 
344 (72·3) 
60 (12·6) 
 
671 (70·3) 
109 (11·4) 
 541 
  542 
Table 2. Efficacy Measures. 543 
Outcome Lenvatinib 
(n = 478) 
Sorafenib 
(n = 476) 
Hazard Ratio  
(95% CI) 
Investigator review per mRECIST    
Median (95% CI) overall survival — mo 13.6 (12·1−14·9) 12·3 (10·4−13·9) 0·92 (0·79−1·06) 
Median (95% CI) progression-free survival — 
mo 
7·4 (6·9−8·8) 3·7 (3·6−4·6) 0·66 (0·57−0·77) 
P<0·0001 
Median (95% CI) time to progression — mo 8·9 (7·4−9·2) 3·7 (3·6−5·4) 0·63 (0·53−0·73) 
P<0·0001 
Objective response rate* — no. (%) 
95% CI 
Complete response 
Partial response 
Stable disease 
Durable stable disease lasting ≥23 weeks 
Progressive disease 
Unknown/not evaluable 
115 (24·1) 
20·2−27·9 
6 (1·3) 
109 (22·8) 
246 (51·5) 
167 (34·9) 
71 (14·9) 
46 (9·6) 
44 (9·2) 
6·6−11·8 
2 (0·4) 
42 (8·8) 
244 (51·3) 
139 (29·2) 
147 (30·9) 
41 (8·6) 
3·13† (2·15−4·56) 
P<0·0001 
Disease control rate‡ — no. (%) 
95% CI 
361 (75·5) 
71·7−79·4 
288 (60·5) 
56·1−64·9 
 
Blinded independent imaging review per 
mRECIST 
   
Median (95% CI) progression-free survival 
— mo 
7·3 (5·6−7·5) 3·6 (3·6−3·7) 0·64 (0·55−0·75) 
P<0·0001 
Median (95% CI) time to progression — 
mo 
7·4 (7·2−9·1) 3.7 (3·6−3·9) 0.60 (0·51−0·71) 
P<0·0001 
Objective response rate* — no. (%) 
95% CI 
Complete response 
Partial response 
Stable disease 
   Durable stable disease lasting ≥23 weeks 
Progressive disease 
Unknown/not evaluable 
194 (40·6) 
36·2−45·0 
10 (2·1) 
184 (38·5) 
159 (33·3) 
   84 (17·6) 
79 (16·5) 
46 (9·6) 
59 (12·4) 
9·4−15·4 
4 (0·8) 
55 (11·6) 
219 (46·0) 
   90 (18·9) 
152 (31·9) 
46 (9·7) 
5·01† 
(3·59−7·01) 
P<0·0001 
Disease control rate‡ — no. (%) 
95% CI 
353 (73·8) 
69·9−77·8 
278 (58·4) 
54·0−62·8 
 
Blinded independent imaging review per 
RECIST 1.1  
   
Median (95% CI) progression-free survival 
— mo 
7·3 (5·6−7·5) 3·6 (3·6−3·9) 0·65 (0·56−0·77) 
P<0·0001 
Median (95% CI) time to progression — 
mo 
7·4 (7·3−9·1) 3·7 (3·6−5·4) 0·61 (0·51−0·72) 
P<0·0001 
Objective response rate* — no. (%) 
95% CI 
Complete response 
90 (18·8) 
15·3−22·3 
2 (0·4) 
31 (6·5) 
4·3−8·7 
1 (0·2) 
3·34† 
(2·17−5·14) 
P<0·0001 
Partial response 
Stable disease 
   Durable stable disease lasting ≥23 weeks 
Progressive disease 
Unknown/not evaluable 
88 (18·4) 
258 (54·0) 
   163 (34·1) 
84 (17·6) 
46 (9·6) 
30 (6·3) 
250 (52·5) 
   118 (24·8) 
152 (31·9) 
43 (9·0) 
Disease control rate‡ — no. (%) 
95% CI 
348 (72·8) 
68·8−76·8 
281 (59·0) 
54·6−63·5 
 
*Objective response is defined as complete response + partial response, according to modified 544 
Response Evaluation Criteria in Solid Tumours or Response Evaluation Criteria in Solid Tumours v1·1. 545 
†Odds ratio. ‡Disease control is defined as complete response + partial response + stable disease.  546 
CI, confidence interval.  547 
Table 3. Adverse Events. 548 
 Lenvatinib 
(n = 476) 
Sorafenib 
(n = 475) 
Total treatment-emergent 
adverse events— no. (%) 
470 (98·7) 472 (99·4) 
Total treatment-related 
treatment-emergent adverse 
events— no. (%) 
 
447 (93·9) 
 
452 (95·2) 
Treatment-emergent adverse 
events of grade ≥3— no. (%) 
357 (75·0) 316 (66·5) 
Treatment-related treatment-
emergent adverse events of 
grade ≥3— no. (%) 
 
270 (56·7) 
 
231 (48·6) 
 
Serious treatment-emergent 
adverse events — no. (%) 
 
205 (43·1) 
 
144 (30·3) 
Serious treatment-related 
treatment-emergent adverse 
events — no. (%) 
84 (17·6) 48 (10·1) 
Treatment-emergent adverse 
events occurring in ≥15% of 
patients in either treatment 
group 
Any grade Grade ≥ 3 Any grade Grade ≥ 3 
Palmar-plantar 
erythrodysaesthesia 
128 (26·9) 14 (2·9) 249 (52·4) 54 (11·4) 
Diarrhoea 184 (38·7) 20 (4·2) 220 (46·3) 20 (4·2) 
Hypertension 201 (42·2) 111 (23·3) 144 (30·3) 68 (14·3) 
Decreased appetite 162 (34·0) 22 (4·6) 127 (26·7) 6 (1·3) 
Decreased weight 147 (30·9) 36 (7·6) 106 (22·3) 14 (2·9) 
Fatigue 141 (29·6) 18 (3·8) 119 (25·1) 17 (3·6) 
Alopecia 14 (2·9) 0 (0) 119 (25·1) 0 (0) 
Proteinuria 117 (24·6) 27 (5·7) 54 (11·4) 8 (1·7) 
Dysphonia 113 (23·7) 1 (0·2) 57 (12·0) 0 (0) 
Nausea 93 (19·5) 4 (0·8) 68 (14·3) 4 (0·8) 
Abdominal pain 81 (17·0) 8 (1·7) 87 (18·3) 13 (2·7) 
Decreased platelet count  87 (18·3) 26 (5·5) 58 (12·2) 16 (3·4) 
Elevated aspartate 
aminotransferase 
65 (13·7) 24 (5·0) 80 (16·8) 38 (8·0) 
Hypothyroidism 78 (16·4) 0 (0) 8 (1·7) 0 (0) 
Vomiting  77 (16·2) 6 (1·3) 36 (7·6) 5 (1·1) 
Constipation 76 (16·0) 3 (0·6) 52 (10·9) 0 (0) 
Rash 46 (9·7) 0 (0) 76 (16·0) 2 (0·4) 
 549 
  550 
Figure 1. Kaplan-Meier Estimate of Overall Survival and Progression-free Survival. 551 
 552 
Kaplan-Meier estimates of overall survival by treatment group are shown in panel A. Panel B shows 553 
progression-free survival by modified Response Evaluation Criteria in Solid Tumours. 554 
CI denotes confidence interval, and HR hazard ratio. 555 
 556 
Figure 2. Forest Plots Indicating Hazard Ratios for Overall Survival and Progression-free Survival in 557 
Subgroup Analyses. 558 
 559 
Subgroup analyses of overall survival indicating associated hazard ratio and 95% confidence interval are 560 
shown in panel A. Panel B shows subgroup analyses of progression-free survival indicating the 561 
associated hazard ratio and 95% confidence interval.  562 
AFP denotes alpha-fetoprotein, BCLC Barcelona Clinic Liver Cancer, CI confidence interval, and HR 563 
hazard ratio. 564 
 565 
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